RA Capital Management L.P. Lowers Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)

RA Capital Management L.P. lessened its position in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 20.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,517,418 shares of the company's stock after selling 379,354 shares during the quarter. RA Capital Management L.P. owned about 2.65% of Structure Therapeutics worth $41,152,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. ANTIPODES PARTNERS Ltd lifted its holdings in Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after purchasing an additional 553 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Structure Therapeutics by 4,155.6% in the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock worth $31,000 after buying an additional 1,122 shares in the last quarter. FNY Investment Advisers LLC purchased a new position in shares of Structure Therapeutics in the fourth quarter worth about $40,000. Virtus ETF Advisers LLC boosted its position in Structure Therapeutics by 25.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after acquiring an additional 455 shares during the last quarter. Finally, Assetmark Inc. grew its stake in Structure Therapeutics by 72.3% during the 4th quarter. Assetmark Inc. now owns 2,271 shares of the company's stock valued at $62,000 after acquiring an additional 953 shares in the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Stifel Nicolaus began coverage on Structure Therapeutics in a report on Wednesday, January 8th. They set a "buy" rating and a $50.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 target price on shares of Structure Therapeutics in a research note on Tuesday, April 22nd. William Blair started coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They set an "outperform" rating on the stock. Finally, Citigroup began coverage on shares of Structure Therapeutics in a research report on Friday. They set a "buy" rating and a $60.00 price objective for the company. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $78.63.

Structure Therapeutics Trading Down 0.9 %

GPCR traded down $0.24 on Friday, hitting $27.09. The company had a trading volume of 739,761 shares, compared to its average volume of 922,943. The company's fifty day moving average price is $20.52 and its 200 day moving average price is $27.38. Structure Therapeutics Inc. has a 1 year low of $13.22 and a 1 year high of $62.74. The firm has a market cap of $1.55 billion, a P/E ratio of -36.61 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. On average, analysts predict that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.